Avalo Therapeutics (AVTX) Cash & Equivalents (2014 - 2026)

Avalo Therapeutics (AVTX) has 13 years of Cash & Equivalents data on file, last reported at $147000.0 in Q1 2026.

• Quarterly Cash & Equivalents rose 137.1% year-over-year to $147000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $147000.0 (up 137.1% YoY) and the FY2025 annual result came in at $15.9 million, down 88.21% from the prior year.
• Cash & Equivalents retreated to $147000.0 in Q1 2026, from $15.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $134.5 million in Q4 2024 to a low of $4000.0 in Q1 2024.
• A 5-year average of $19.5 million and a median of $3.2 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2023 — Cash & Equivalents surged 49333.33% — and 2024, when it tumbled 99.98%.
• Tracing AVTX's Cash & Equivalents over 5 years: stood at $15000.0 in 2022, then surged by 49333.33% to $7.4 million in 2023, then soared by 1714.51% to $134.5 million in 2024, then plunged by 88.21% to $15.9 million in 2025, then slumped by 99.07% to $147000.0 in 2026.
• The last three Cash & Equivalents figures came in at $147000.0 (Q1 2026), $15.9 million (Q4 2025), and $90000.0 (Q3 2025), per Business Quant data.